Omeros Corp OMER

US Pharmaceuticals

$20.08 ▼ -0.25% ($-0.05)

🎢 High Beta

Open $20.39

Prev Close $20.13

Day Range $19.66 – $20.61

52W Range $4.06 – $21.24

Market Cap $1.45B

P/E (TTM) 11.66

Beta 3.01

EPS (TTM) $1.52

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2009-10-08
Shares Out.	72,380,000
Website	omeros.com/ ↗
Phone	12066765000
Employees	175
Revenue	$28.5M
Gross Profit	$27.7M
Net Income	$13.2M
Free Cash Flow	-$68.7M
Total Assets	$286.8M
Total Liabilities	$338.2M
Equity	-$51.3M

About Omeros Corp

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Omeros Corp is a publicly traded company under the ticker symbol OMER on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.